Matterworks Secures Series A Funding to Advance AI in Biology
Matterworks, Inc., known for its innovative approach in unlocking unstructured molecular data for predictive biology, has successfully completed a Series A funding round. This funding was primarily spearheaded by Lewis & Clark Partners and OMX Ventures, along with participation from a variety of other investors including Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia. The infusion of capital will enable Matterworks to develop its Model as a Service (MaaS) business model and enhance its machine learning capabilities along with scientific operations.
Leadership Insights on Funding and Future Goals
Jack Geremia, the CEO and Co-Founder of Matterworks, expressed his enthusiasm regarding the partnership with Lewis & Clark Partners. He remarked on the potential for accelerated machine intelligence innovations that aim to address the mounting costs associated with life science research and development. Geremia's leadership will ensure that Matterworks utilizes the strategic funds for substantial growth in its AI capabilities.
Carolyn Fritz of Lewis & Clark Partners, who recently joined Matterworks' Board of Directors, emphasized the importance of collaboration with customers. She stated that Matterworks' AI platform significantly reduces costs and enhances throughput in mass spectrometry quantitation, setting the stage for the commercialization of their groundbreaking technology.
Advancements in Mass Spectrometry
According to Craig Asher, a Managing Director from OMX Ventures, Matterworks is on the verge of a pivotal transformation in biology through AI. The firm aims to democratize access to mass spectrometry data, making previously complex analyses available to all biologists. This shift is compared to significant breakthroughs such as single-cell sequencing, highlighting the substantial impact Matterworks' technology could have on the field.
Overview of Matterworks' Innovations
Matterworks’ flagship product, the Large Spectral Models (LSMs), utilizes self-supervised machine intelligence to facilitate direct interpretation of molecular-omic data. Their innovative tool, PyxisTM, which was introduced in 2024, represents the first generative AI developed for comprehensive untargeted molecular annotation. This product is set to unlock new data modalities essential for understanding and forecasting complex biological outcomes.
About the Investment Partners
Lewis & Clark Partners is a St. Louis-based investment group with a strong commitment to advancing companies leading in the science, health, food, and agricultural innovation sectors. The firm is dedicated to nurturing growth-stage companies that have the potential to scale effectively in national and global markets. The team consists of seasoned professionals ranging from founders to scientists, providing expertise in every investment made.
OMX Ventures, another key player in this funding round, positions itself at the forefront of a new bioengineering era. The venture capital firm focuses on early-stage investments that intersect biology, big data, and artificial intelligence, targeting advancements in therapeutics, bio tools, diagnostics, and synthetic biology platforms. Their investments aim to develop improved tools and products for a variety of applications.
Frequently Asked Questions
What is the focus of Matterworks, Inc.?
Matterworks focuses on utilizing AI to unlock unstructured molecular data for applications in predictive biology, enhancing research capabilities.
Who were the lead investors in the Series A funding?
The Series A funding was led by Lewis & Clark Partners and OMX Ventures, with participation from several other venture firms.
How will the funding benefit Matterworks?
The funding will help Matterworks grow its Model as a Service business and improve its machine learning and scientific operations, ultimately fostering innovation.
What is the Large Spectral Models (LSMs) product?
The LSMs provided by Matterworks leverage self-supervised machine intelligence for the interpretation of molecular-omic data, facilitating advanced biological analysis.
Why is mass spectrometry significant in biological research?
Mass spectrometry offers critical insights into biological molecules, making it an invaluable tool for researchers in understanding complex biological systems and pathways.
